Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
F 79.4 0.80% 0.63
BMRN closed up 0.8 percent on Friday, April 16, 2021, on 74 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical BMRN trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
50 DMA Resistance Bearish 0.80%
Older End-of-Day Signals for BMRN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioMarin Pharmaceutical Inc. Description

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Treatment Of Cancer Rare Diseases Drug Discovery Autoimmune Disease Virotherapy Genetic Disease Serious Diseases Metabolic Disease Biopharmaceuticals Inborn Errors Of Metabolism Genzyme Enzyme Replacement Therapy Lysosomal Storage Disorder Mucopolysaccharidosis Phenylketonuria Pku Pompe Disease Achondroplasia Biomarin Pharmaceutical Glycogen Storage Disorder Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Pharmaceutical Wholesalers

Is BMRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 131.945
52 Week Low 71.35
Average Volume 1,118,955
200-Day Moving Average 86.96
50-Day Moving Average 79.43
20-Day Moving Average 77.16
10-Day Moving Average 78.14
Average True Range 1.88
ADX 20.14
+DI 20.86
-DI 24.14
Chandelier Exit (Long, 3 ATRs ) 74.21
Chandelier Exit (Short, 3 ATRs ) 78.41
Upper Bollinger Band 80.09
Lower Bollinger Band 74.23
Percent B (%b) 0.88
BandWidth 7.59
MACD Line -0.04
MACD Signal Line -0.47
MACD Histogram 0.4323
Fundamentals Value
Market Cap 14.41 Billion
Num Shares 182 Million
EPS 4.56
Price-to-Earnings (P/E) Ratio 17.41
Price-to-Sales 8.16
Price-to-Book 3.56
PEG Ratio 0.92
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.70
Resistance 3 (R3) 81.51 80.55 81.31
Resistance 2 (R2) 80.55 79.97 80.65 81.18
Resistance 1 (R1) 79.98 79.61 80.27 80.17 81.06
Pivot Point 79.02 79.02 79.17 79.12 79.02
Support 1 (S1) 78.45 78.44 78.74 78.64 77.74
Support 2 (S2) 77.49 78.08 77.59 77.62
Support 3 (S3) 76.92 77.49 77.49
Support 4 (S4) 77.11